Event Overview

Typically, viral infections are not desirable; however, bacterial viruses, or bacteriophages, are promising therapeutic agents against multi-drug resistant microbes. Many phages have a narrow host range, infecting only one bacterial species or strain. Researchers hope to transform these viruses into targeted therapies for devastating bacterial infections. In this webinar from The Scientist, bacteriophage experts Paul Turner and Jason Gill will describe their research on phages that destroy drug resistant pathogens, their experiences with emergency patient treatment, and challenges and successes in obtaining FDA approval for this experimental therapy.

Topics to be covered
  • Genomics and distribution of Staphylococcus, Burkholderia, and Klebsiella species
  • Circumventing bacterial phage resistance
  • Phages in emergency patient treatment
  • Regulatory considerations surrounding clinical phage use
Thursday, October 29, 2020
2:30 - 4:00 PM, Eastern Standard Time


Paul Turner, PhD
Rachel Carson Professor of Ecology & Evolutionary Biology
Yale University
Microbiology Faculty
Yale School of Medicine

Jason Gill, PhD
Associate Director
Center for Phage Technology
Associate Professor, Departments of Animal Science, Microbial Pathogenesis and Immunology, and Genetics
Texas A&M University


Register Now

Optimizing Lab Ultrafiltration Workflows: From Molecule Separation to Diagnostics

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be held in confidence and will be shared with the sponsoring vendor(s) of this webinar. We may use the information to contact you about your account and to let you know about related programs and products; you may opt-out at any time. This allows The Scientist to keep these webinars free of charge for our readers.